pharma · Hemophagocytic lymphohistiocytosis (HLH) · Multiple sclerosis
PARItec
Pari Pharma GmbH
Pari Pharma is a pharma organization headquartered in Starnberg, DE. Primary therapeutic focus areas include Hemophagocytic lymphohistiocytosis (HLH), Multiple sclerosis, Acute Myocardial Infarction, Familial Mediterrane
Starnberg, DE HQ
28 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Starnberg, DE
- Employees
- 28
- Programs
- 248
- Drugs
- 362
- Patents
- 0
P150941J
Phase 2 · small molecule · Adults diagnosed with SJS-TEN with at least 10% of body surface area involved
P150941J for Adults diagnosed with SJS-TEN with at least 10% of body surface area involved is a Phase 2 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Internal code P150941J
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pari Pharma GmbH
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Adults diagnosed with SJS-TEN with at least 10% of body surface area involved
- Status
- active
- Trials
- 1